Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8791650 | 0.98 | NAPRT (0.45) | NAPRTHSD17B10MAPTTSHRTP53 | |
| SCHEMBL11350456 | 0.86 | NAPRT (0.52) | NAPRTHSD17B10MAPTTSHRTP53 | |
| SCHEMBL5954425 | 0.83 | HPGD (0.49) | MAPTSMN1; SMN2RAB9AHPGDNPC1 | |
| SCHEMBL5954995 | 0.83 | HPGD (0.56) | EPHX1SMN1; SMN2PDK1PDK2PDK3 | |
| SCHEMBL5954475 | 0.83 | LMNA (0.49) | POLB | |
| SCHEMBL19707372 | 0.83 | MAPT (0.47) | MAPTSMN1; SMN2RAB9AHPGDNPC1 | |
| SCHEMBL3076892 | 0.83 | MAPT (0.50) | NAPRTHSD17B10MAPTTSHRTP53 | |
| SCHEMBL5514973 | 0.82 | NAPRT (0.46) | NAPRTHSD17B10MAPTTSHRTP53 | |
| SCHEMBL25041715 | 0.81 | NR1H4 (0.51) | MAPTEPHX2SMN1; SMN2PDK1PDK2 | |
| SCHEMBL9756879 | 0.81 | MAPT (0.59) | NAPRTHSD17B10MAPTTSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106800536-A | A kind of preparation method of the miscellaneous Shandong amine of grace | 南京慧博生物科技有限公司 | 2017-06-06 | — | — | CN | claimed |
| EP-0012379-B1 | LAQUER MIXTURE AND COATING MATERIAL CONTAINING POLYAMIDE HYDANTOINS | BAYER AG (DE) | 1983-06-01 | — | — | EP | claimed |
| EP-0012381-B1 | PROCESS FOR THE PREPARATION OF COMPOUNDS CONTAINING HYDANTOIN GROUPS | BAYER AG (DE) | 1982-12-15 | — | — | EP | claimed |
| US-4281095-A | Coating compositions obtained by reacting amino carboxylic acids derivatives with polyisocyanates and compounds containing carboxylic groups to produce polymers containing hydantoin rings and amide groups | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-28 | — | — | US | claimed |
| US-4269750-A | Process for the preparation of polymers containing hydantoin groups | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-26 | — | — | US | claimed |
| EP-4681207-A2 | METHODS FOR PREDICTING RESPONSE TO PHARMACOLOGICAL AGENTS IN PATIENTS WITH OBESITY | Phenomix Sciences, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4680343-A1 | PROTEIN-PROTEIN INTERACTION STABILIZERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20250319054-A1 | Synthetic Eicosanoid Analogues for the Treatment and Prevention of Diseases Associated with Increased GDF15 Plasma Concentration | OMEICOS THERAPEUTICS GMBH (DE) | 2025-10-16 | — | — | US | disclosed |
| US-20250263393-A1 | FAP INHIBITORS | SHANGHAI SINOTAU BIOTECH. CO., LTD (CN) | 2025-08-21 | — | — | US | disclosed |
| EP-4590664-A1 | INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN AND USE THEREOF | Shanghai Sinotau Biotech. Co., Ltd (CN) | 2025-07-30 | — | — | EP | disclosed |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | OMEICOS THERAPEUTICS GMBH (DE) | 2025-07-29 | — | — | US | disclosed |
| US-20250127937-A1 | FAP INHIBITOR | UNIV HEIDELBERG (DE) | 2025-04-24 | — | — | US | disclosed |
| EP-0253007-A1 | Stabilized polymers, novel stabilizers, and synthesis thereof | The B.F. GOODRICH Company (US) | 1988-01-20 | — | — | EP | disclosed |
| US-4601839-A | A-AMINOACETAMIDES | THE B. F. GOODRICH COMPANY (US) | 1986-07-22 | — | — | US | disclosed |
| US-4466915-A | Non-catalytic ketoform syntheses | THE B. F. GOODRICH COMPANY (US) | 1984-08-21 | — | — | US | disclosed |
| EP-0104645-A1 | Non-catalytic ketoform syntheses | The B.F. GOODRICH Company (US) | 1984-04-04 | — | — | EP | disclosed |
| US-4310429-A | HEAT AND OXIDATION RESISTANT AMINOACETAMIDES | THE B. F. GOODRICH COMPANY (US) | 1982-01-12 | — | — | US | disclosed |
| US-4281095-A | Coating compositions obtained by reacting amino carboxylic acids derivatives with polyisocyanates and compounds containing carboxylic groups to produce polymers containing hydantoin rings and amide groups | BAYER AKTIENGESELLSCHAFT (DE) | 1981-07-28 | — | — | US | disclosed |
| US-4269750-A | Process for the preparation of polymers containing hydantoin groups | BAYER AKTIENGESELLSCHAFT (DE) | 1981-05-26 | — | — | US | disclosed |
| EP-0007182-A1 | Stabilized polymers, novel stabilizers and synthesis thereof | The B.F. GOODRICH Company (US) | 1980-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319054-A1 | Synthetic Eicosanoid Analogues for the Treatment and Prevention of Diseases Associated with Increased GDF15 Plasma Concentration | IL15, ALOX15, FABP3 | NAPRT 2791/4885HSD17B10 309/4885MAPT 4543/4885 |
| US-20250127937-A1 | FAP INHIBITOR | FAP, APC, FIBP | NAPRT 601/4885HSD17B10 2946/4885MAPT 1720/4885 |
| US-20250263393-A1 | FAP INHIBITORS | FAP, APC, FIBP | NAPRT 471/4885HSD17B10 2339/4885MAPT 2392/4885 |
| US-12370158-B2 | Analogs of CYP-eicosanoids for use in treating or preventing a disorder associated with neovascularization and/or inflammation | ALOX5, ALOX15B, ALOX15 | NAPRT 736/4885HSD17B10 100/4885MAPT 4420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.